Skip to content

A Study of Residual Curarization Incidence in China

A Perspective, Multicentre, Randomized,Blind Study of Residual Curarization Incidence in China

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01690338
Enrollment
6090
Registered
2012-09-21
Start date
2012-10-31
Completion date
2014-12-31
Last updated
2013-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perioperative/Postoperative Complications, PORC (Postoperative Residual Curarization)

Keywords

TOFr (train of four ratio), airway extubation, PACU (postanesthesia care unit), PORC (postoperative residual curarization)

Brief summary

The purpose of this study is to determine the incidence of residual curarization in PACU and relevant risk factors.

Detailed description

In the last twenty years, residual curarization in PACU (Post Anesthesia Care Unit) has become a common problem in clinical practice and poses high risk to patients. The residual curarization incidence of Neuromuscular blocking agents (NMBA) varies very much between different studies. These differences indicates the necessity of further study. In China, there is no common view of the harmfulness of residual curarization and its complications. The consensus on the necessity of neuromuscular transmission monitoring and neuromuscular blockade antagonist has not been reached yet. There is also no similar large-scale survey in China. In this case, the investigators conduct this large scale multicentre study, which is designed to learn the incidence of residual curarization and its complications. Further analysis of risk factors will also been made. All these efforts are hoped to fill the data gap and provide reliable evidences for rational use of NMBA.

Interventions

Administrative protocol of Vecuronium Bromide is determined by each caregiver's clinical experience.

DRUGRocuronium

Administrative protocol of rocuronium is determined by each caregiver's clinical experience.

DRUGCisatracurium

Administrative protocol of cisatracurium is determined by each caregiver's clinical experience

Sponsors

Ruijin Hospital
CollaboratorOTHER
RenJi Hospital
CollaboratorOTHER
Shanghai Zhongshan Hospital
CollaboratorOTHER
The First Affiliated Hospital of Guangzhou Medical University
CollaboratorOTHER
West China Hospital
CollaboratorOTHER
Eastern Hepatobiliary Surgery Hospital
CollaboratorOTHER
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
CollaboratorOTHER
Zhujiang Hospital
CollaboratorOTHER
Chinese PLA General Hospital
CollaboratorOTHER
First Affiliated Hospital, Sun Yat-Sen University
CollaboratorOTHER
The First Affiliated Hospital of Zhengzhou University
CollaboratorOTHER
Tianjin Medical University General Hospital
CollaboratorOTHER
Xiangya Hospital of Central South University
CollaboratorOTHER
Central South University
CollaboratorOTHER
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
CollaboratorOTHER
First Affiliated Hospital of Xinjiang Medical University
CollaboratorOTHER
Peking Union Medical College Hospital
CollaboratorOTHER
First Affiliated Hospital of Zhejiang University
CollaboratorOTHER
China Medical University Hospital
CollaboratorOTHER
Hebei Medical University Fourth Hospital
CollaboratorOTHER
Tongji Hospital
CollaboratorOTHER
Peking University First Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Aged 18 or older * Nondepolarized NMBA will be given during surgery and tracheal extubation will be performed after surgery * Willing to comply with all study procedures and provide signed and dated informed consent

Exclusion criteria

* Allergic reaction to gel electrode * Neuromuscular disorders and hepatic or renal dysfunction * Scheduled to receive mechanical ventilation therapy * Involved in other clinical trials * Body position and surgical procedure affecting TOF-Watch SX normal function

Design outcomes

Primary

MeasureTime frameDescription
incidence of TOFr<0.9From tracheal extubation to 1 minute after extubationOnce tracheal extubation is performed after the surgery is over, monitor the neuromuscular transmission function (TOF ratio) immediately.

Secondary

MeasureTime frameDescription
Incidence of TOFr<0.9One minute after arriving at PACUWhen patients arrive at PACU(an expected average of 15 minutes after surgery is over), monitor the neuromuscular transmission function (TOF ratio) immediately
Incidence of TOFr<0.7From tracheal extubation to 1 minute after extubationOnce tracheal extubation is performed after the surgery is over, monitor the neuromuscular transmission function (TOF ratio) immediately.

Other

MeasureTime frameDescription
any sign of residual curarization (listed in description below)First 24h after surgerySign of residual curarization : 1. dyspnea 2. weak hand-grip force 3. Head lift or leg lift time shorter than 5s 4. aspiration 5. respiratory rate \>20/min 6. hypoxemia (SpO2\<90% when O2\>3L/min)
pulmonary complications (See description)participants will be followed for the duration of hospital stay, an expected average of one weekpulmonary complications 1. pneumonia 2. pulmonary atelectasis 3. mechanical ventilation required

Countries

China

Contacts

Primary ContactXinmin Wu, Doctor
xmwu2784@hotmail.com+86 13910616740

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026